Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
Melbourne (Australia) | 9 January 2023
Telix today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9–12 January) in San Francisco.
As part of the Company’s presentation, Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.). This is an increase of 39% on Q3 2022, and a total of AU$149.7M (US$100.4M) revenue since Illuccix launch.
Group CEO and Managing Director, Dr. Christian Behrenbruch stated, “We are very pleased with the continued sales momentum since launching Illuccix in the United States in April 2022. The continued strong sales growth reflects our differentiated business model and execution in the U.S. market. We look forward to updating institutional investors on the progress of our commercial activities and our broader pipeline, including our recent excellent results in renal cancer.”
The presentation will take place on Wednesday 11 January 2023 at 11.00am PST (Thursday 12 January 6.00am AEDT). A live webcast and recording will be available at the following link: https://jpmorgan.metameetings.net/events/healthcare23/sessions/44024-telix-pharmaceuticals/webcast?gpu_only=true&kiosk=true
A complete announcement on global revenue, cash balance and business activities for the fourth quarter (ended 31 December 2022) will be included in the Appendix 4C and activities report to be lodged on the ASX on Wednesday 18 January (AEDT). Telix expects to report its Full Year Financial Results for the year ended 31 December 2022 on Monday 27 February 2023.
To read the full ASX release click here
To view the investor presentation click here